Latest & greatest articles for calcium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on calcium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on calcium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for calcium

21. Comparison of mineral trioxide aggregate and calcium hydroxide of pulpotomy in immature permanent teeth: a systematic review and meta-analysis

Comparison of mineral trioxide aggregate and calcium hydroxide of pulpotomy in immature permanent teeth: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

22. Calcium channel blockers for prevention of peripheral vascular disease in hypertensive patients

Calcium channel blockers for prevention of peripheral vascular disease in hypertensive patients Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

23. The impact of blood calcium concentration during the hyperacute phase of major bleeding: a systematic review

The impact of blood calcium concentration during the hyperacute phase of major bleeding: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

24. The effects of calcium hydroxide as an intra-canal medication on postoperative pain and bacterial load during primary root canal therapy in patients with pulp necrosis and apical periodontitis: a systematic review and meta-analysis

The effects of calcium hydroxide as an intra-canal medication on postoperative pain and bacterial load during primary root canal therapy in patients with pulp necrosis and apical periodontitis: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate

2019 PROSPERO

25. Triple Antibiotic Solution Promotes Similar Antibacterial Effects as Calcium Hydroxide/2% Chlorhexidine When Used as an Intracanal Medicament

Triple Antibiotic Solution Promotes Similar Antibacterial Effects as Calcium Hydroxide/2% Chlorhexidine When Used as an Intracanal Medicament UTCAT3361, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Triple Antibiotic Solution Promotes Similar Antibacterial Effects as Calcium Hydroxide/2% Chlorhexidine When Used as an Intracanal Medicament Clinical Question In patients undergoing non-surgical therapy in a tooth (...) diagnosed with pulpal necrosis, does the use of triple antibiotic paste as an intracanal medicament have better antibacterial efficacy than a calcium hydroxide/chlorhexidine formulation? Clinical Bottom Line Triple antibiotic solution (1 mg/mL) promoted similar antibacterial effects as calcium hydroxide/2% chlorhexidine when used as an intracanal medicament. This is based on several randomized clinical trials in which intracanal medicaments were placed for 7 to 21 days in primary and immature/mature

2018 UTHSCSA Dental School CAT Library

26. Astronaut Cardiovascular Health and Risk Modification (Astro-CHARM) Coronary Calcium Atherosclerotic Cardiovascular Disease Risk Calculator

Astronaut Cardiovascular Health and Risk Modification (Astro-CHARM) Coronary Calcium Atherosclerotic Cardiovascular Disease Risk Calculator Coronary artery calcium (CAC) is a powerful novel risk indicator for atherosclerotic cardiovascular disease (ASCVD). Currently, there is no available ASCVD risk prediction tool that integrates traditional risk factors and CAC.To develop a CAC ASCVD risk tool for younger individuals in the general population, subjects aged 40 to 65 without prior

Full Text available with Trip Pro

2018 EvidenceUpdates

27. Is Adenosine or an Intravenous Calcium Channel Blocker More Effective for Treating Supraventricular Tachycardia? (SRS therapy)

Is Adenosine or an Intravenous Calcium Channel Blocker More Effective for Treating Supraventricular Tachycardia? (SRS therapy) TAKE-HOME MESSAGE Among patients presenting with supraventricular tachycardia, rates of reversion to sinus rhythm and hypotension were similar between patients who were given adenosine or calcium channel blockers. Is Adenosine or an Intravenous Calcium Channel Blocker More Effective for Treating Supraventricular Tachycardia? EBEM Commentators Michael Gottlieb, MD (...) studies, although one study had both a verapamil and a diltiazem treat- ment arm. There was no difference in the rates of reversion to sinus rhythm between adenosine and calcium channel antagonists (Table). Three trials reported on hypotension, with only one case identi?ed in the calcium channel antagonist group. Four studies, comprising 442 patients, evaluated time to reversion, with a signi?cantly reduced time in the adenosine group (mean¼44 seconds) compared with the calcium channel antago- nist

2018 Annals of Emergency Medicine Systematic Review Snapshots

28. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. (PubMed)

Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Pre-eclampsia and eclampsia are common causes of serious morbidity and death. Calcium supplementation may reduce the risk of pre-eclampsia, and may help to prevent preterm birth. This is an update of a review last published in 2014.To assess the effects of calcium supplementation during pregnancy on hypertensive disorders of pregnancy and related maternal and child outcomes.We searched Cochrane (...) Pregnancy and Childbirth's Trials Register, ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP) (18 September 2017), and reference lists of retrieved studies.We included randomised controlled trials (RCTs), including cluster-randomised trials, comparing high-dose calcium supplementation (at least 1 g daily of calcium) during pregnancy with placebo. For low-dose calcium we included quasi-randomised trials, trials without placebo, trials with cointerventions and dose

2018 Cochrane

29. Patiromer sorbitex calcium (Veltassa) - for the treatment of hyperkalaemia in adults

Patiromer sorbitex calcium (Veltassa) - for the treatment of hyperkalaemia in adults 1 patiromer (as patiromer sorbitex calcium) 8.4g and 16.8g powder for oral suspension (Veltassa ® ) SMC2084 Vifor Fresenius Medical Care Renal Pharma UK Ltd 6 July 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following

2018 Scottish Medicines Consortium

30. Calcium

Calcium Top results for calcium - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for calcium The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

31. Empagliflozin, calcium, and SGLT1/2 receptor affinity: another piece of the puzzle (PubMed)

Empagliflozin, calcium, and SGLT1/2 receptor affinity: another piece of the puzzle 30024112 2018 11 14 2018 11 14 2055-5822 5 4 2018 08 ESC heart failure ESC Heart Fail Empagliflozin, calcium, and SGLT1/2 receptor affinity: another piece of the puzzle. 549-551 10.1002/ehf2.12345 Anker Stefan D SD Division of Cardiology and Metabolism, Department of Cardiology (CVK), Berlin-Brandenburg Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin (...) , Charité Universitätsmedizin Berlin, Berlin, Germany. Department of Cardiology and Pneumology, University Medicine Göttingen (UMG), Göttingen, Germany. Butler Javed J Department of Medicine, University of Mississippi, Jackson, MS, USA. eng Editorial Comment 2018 07 19 England ESC Heart Fail 101669191 2055-5822 0 Benzhydryl Compounds 0 Glucosides 0 Sodium-Glucose Transporter 1 HDC1R2M35U empagliflozin IY9XDZ35W2 Glucose SY7Q814VUP Calcium IM ESC Heart Fail. 2018 Aug;5(4):642-648 30117720 Benzhydryl

Full Text available with Trip Pro

2018 ESC heart failure

32. Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia. (PubMed)

Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia. Beta thalassaemia is a common inherited blood disorder. The need for frequent blood transfusions in this condition poses a difficult problem to healthcare systems. The most common cause of morbidity and mortality is cardiac dysfunction from iron overload. The use of iron chelation therapy has reduced the severity of systemic iron overload but specific, non-toxic (...) treatment is required for removal of iron from the myocardium.To assess the effects of calcium channel blockers combined with standard iron chelation therapy in people with transfusion-dependent beta thalassaemia on the amount of iron deposited in the myocardium, on parameters of heart function, and on the incidence of severe heart failure or arrhythmias and related morbidity and mortality.We searched the Cochrane Haemoglobinopathies Trials Register, compiled from electronic database searches

2018 Cochrane

33. Calcium-RasGRP2-Rap1 signaling mediates CD38-induced migration of chronic lymphocytic leukemia cells (PubMed)

Calcium-RasGRP2-Rap1 signaling mediates CD38-induced migration of chronic lymphocytic leukemia cells CD38 is a transmembrane exoenzyme that is associated with poor prognosis in chronic lymphocytic leukemia (CLL). High CD38 levels in CLL cells are linked to increased cell migration, but the molecular basis is unknown. CD38 produces nicotinic acid adenine dinucleotide phosphate and adenosine 5'-diphosphate-ribose, both of which can act to increase intracellular Ca2+ levels. Here we show that CD38

Full Text available with Trip Pro

2018 Blood advances

34. Heparin Oligosaccharides Have Antiarrhythmic Effect by Accelerating the Sodium-Calcium Exchanger (PubMed)

Heparin Oligosaccharides Have Antiarrhythmic Effect by Accelerating the Sodium-Calcium Exchanger Background: Blockage of the Na+/Ca2+ exchanger (NCX) is used to determine the role of NCX in arrhythmogenesis. Trisulfated heparin disaccharide (TD) and Low Molecular Weight Heparins (LMWHs) can directly interact with the NCX and accelerate its activity. Objective: In this work, we investigated the antiarrhythmic effect of heparin oligosaccharides related to the NCX activity. Methods: The effects (...) of heparin oligosaccharides were tested on the NCX current (patch clamping) and intracellular calcium transient in rat cardiomyocytes. The effects of heparin oligosaccharides were further investigated in arrhythmia induced in isolated rat atria and rats in vivo. Results: The intracellular Ca2+ concentration decreases upon treatment with either enoxaparin or ardeparin. These drugs abolished arrhythmia induction in isolated atria. The NCX antagonist KB-R7943 abolished the enoxaparin or ardeparin

Full Text available with Trip Pro

2018 Frontiers in cardiovascular medicine

35. Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults: Preventive Medication

Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults: Preventive Medication Final Update Summary: Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults: Preventive Medication - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 11/16/2018 6:27:19 PM You are here: Final Summary Vitamin D, Calcium, or Combined (...) Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults: Preventive Medication Release Date: April 2018 Recommendation Summary Population Recommendation Grade Men and premenopausal women The USPSTF concludes that the current evidence is insufficient to assess the balance of the benefits and harms of vitamin D and calcium supplementation, alone or combined, for the primary prevention of fractures in men and premenopausal women. Postmenopausal women The USPSTF concludes

2018 U.S. Preventive Services Task Force

36. Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. (PubMed)

Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. Osteoporotic fractures result in significant morbidity and mortality.To update the evidence for benefits and harms of vitamin D, calcium, or combined supplementation for the primary prevention of fractures in community-dwelling adults to inform the US Preventive Services Task Force.PubMed, EMBASE (...) , Cochrane Library, and trial registries through March 21, 2017; references; and experts. Surveillance continued through February 28, 2018.English-language randomized clinical trials (RCTs) or observational studies of supplementation with vitamin D, calcium, or both among adult populations; studies of populations that were institutionalized or had known vitamin D deficiency, osteoporosis, or prior fracture were excluded.Dual, independent review of titles/abstracts and full-text articles and study quality

Full Text available with Trip Pro

2018 JAMA

37. Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults: US Preventive Services Task Force Recommendation Statement. (PubMed)

Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults: US Preventive Services Task Force Recommendation Statement. Because of the aging population, osteoporotic fractures are an increasingly important cause of morbidity and mortality in the United States. Approximately 2 million osteoporotic fractures occurred in the United States in 2005, and annual incidence is projected to increase to more than 3 million fractures by 2025. Within (...) 1 year of experiencing a hip fracture, many patients are unable to walk independently, more than half require assistance with activities of daily living, and 20% to 30% of patients will die.To update the 2013 US Preventive Services Task Force (USPSTF) recommendation on vitamin D supplementation, with or without calcium, to prevent fractures.The USPSTF reviewed the evidence on vitamin D, calcium, and combined supplementation for the primary prevention of fractures in community-dwelling adults

Full Text available with Trip Pro

2018 JAMA

38. Calcium channel blockers are useful in managing Raynaud’s phenomenon

Calcium channel blockers are useful in managing Raynaud’s phenomenon Calcium channel blockers are useful in managing Raynaud’s phenomenon Discover Portal Discover Portal Calcium channel blockers are useful in managing Raynaud’s phenomenon Published on 20 February 2018 doi: Calcium channel blockers, such as nifedipine, are confirmed as useful in reducing the frequency, duration, severity of attacks, pain and disability associated with Raynaud’s phenomenon. People had two to six fewer attacks per (...) week on average with treatment, and 13 without. Raynaud’s is a disorder which reduces blood flow to the fingers and toes as a result of the blood vessels tightening and going into spasm in the cold. This updated review suggested that calcium channel blockers may be more effective in higher doses than lower doses and help primary symptoms rather than the secondary form of Raynaud’s that is due to underlying disease. Most research has been into nifedipine. Although no serious adverse events while

2018 NIHR Dissemination Centre

39. Calcium and vitamin D supplementation and increased risk of serrated polyps: results from a randomised clinical trial

Calcium and vitamin D supplementation and increased risk of serrated polyps: results from a randomised clinical trial Serrated lesions such as sessile serrated adenomas or polyps (SSA/Ps) are important colorectal cancer precursors, but aetiological factors for these lesions are largely unknown. We aimed to determine the effects of calcium and vitamin D supplementation on the incidence of serrated polyps (SPs) in general and hyperplastic polyps and SSA/Ps specifically.Participants with one (...) or more adenoma at baseline were randomised to receive 1200 mg/day of elemental calcium, 1000 IU/day of vitamin D3, both or neither agent. Treatment continued for 3 or 5 years, when risk of polyps was determined from surveillance colonoscopy (treatment phase). Outcomes after treatment ceased were also assessed (observational phase). Adjusted risk ratios (aRRs) of SPs were determined via multivariable generalised linear models.SPs were diagnosed in 565 of 2058 (27.5%) participants during the treatment

2018 EvidenceUpdates

40. Calcium channel blockers for antipsychotic-induced tardive dyskinesia. (PubMed)

Calcium channel blockers for antipsychotic-induced tardive dyskinesia. Schizophrenia and related disorders affect a sizable proportion of any population. Antipsychotic medications are the primary treatment for these disorders. Antipsychotic medications are associated with a variety of adverse effects including tardive dyskinesia. Dyskinesia is a disfiguring movement disorder of the orofacial region that can be tardive (having a slow or belated onset). Tardive dyskinesia is difficult to treat (...) , despite experimentation with several treatments. Calcium channel blockers (diltiazem, nifedipine, nimodipine, verapamil, flunarizine) have been among these experimental treatments.To determine the effects of calcium channel blocker drugs (diltiazem, nifedipine, nimodipine, verapamil) for treatment of neuroleptic-induced tardive dyskinesia in people with schizophrenia, schizoaffective disorder or other chronic mental illnesses.We searched the Cochrane Schizophrenia Group Trials Register (July 2015

2018 Cochrane